MeiraGTx Holdings plc SEC filings MGTX
MeiraGTx Holdings plc has 509 filings in SEC EDGAR's recent list, going back to Mar 29, 2018. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 23, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 30, 2026 | — |
| DEF 14A | Proxy statement | Apr 30, 2026 | Jun 11, 2026 |
| DEFA14A | Additional proxy material | Apr 30, 2025 | — |
| DEF 14A | Proxy statement | Apr 30, 2025 | Jun 12, 2025 |
| DEFA14A | Additional proxy material | Apr 25, 2024 | — |
| DEF 14A | Proxy statement | Apr 25, 2024 | Jun 6, 2024 |
| DEFA14A | Additional proxy material | Apr 27, 2023 | — |
| DEF 14A | Proxy statement | Apr 27, 2023 | Jun 8, 2023 |
| DEFA14A | Additional proxy material | Jan 20, 2023 | — |
| DEF 14A | Proxy statement | Dec 23, 2022 | Jan 24, 2023 |
| DEF 14A | Proxy statement | May 2, 2022 | Jun 7, 2022 |
| DEFA14A | Additional proxy material | Apr 28, 2021 | — |
| DEF 14A | Proxy statement | Apr 28, 2021 | Jun 10, 2021 |
| DEFA14A | Additional proxy material | May 26, 2020 | — |
| DEFA14A | Additional proxy material | Apr 21, 2020 | — |
| DEF 14A | Proxy statement | Apr 21, 2020 | Jun 2, 2020 |
| DEFA14A | Additional proxy material | Apr 29, 2019 | — |
| DEF 14A | Proxy statement | Apr 29, 2019 | Jun 19, 2019 |
| PRE 14A | Preliminary proxy statement | Apr 12, 2019 | Jun 19, 2019 |
Showing 19 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- MGTX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1735438
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.